|
|
1095 Colby Avenue, Suite C
Menlo Park, CA 94025-2334 USA
phone:650-333-3150
fax:650-323-6215
|
|
| Symbol |
Private |
| Founded |
0 |
| Employees |
|
|
|
| www.colbypharmaceuticals.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Drugs for androgen-dependent and androgen-independent tumors |
|
| Management |
| David Zarling PhD MBA, Chief Executive Officer; Hirak Basu PhD, Chief Scientific Officer; M Mehta MD, Chief Medical Officer; Anne Vallerga, PhD, VP; Alex Zhavoronkov, PhD, Business Development Director |
| |
|
|
| |
|
| Keywords |
| small molecule therapeutics, oxidative stress, cancer, prostate, oncology, urology |
|
|
|
| Description |
|
Colby Pharmaceutical Company is developing new signal transduction, oxidative-stress, and hypoxia-inhibitor drugs to treat tumors that are resistant to therapy. Colby’s lead drug candidate, CPC-100, is intended for prostate cancer patients who have already been through surgery or radiation for their primary prostate tumor and have yielded insufficient results with Androgen Depletion Therapy. This anti-Androgenic, anti-inflammatory, multi-targeted transduction inhibitor drug is intended for the treatment of both Androgen-dependent and Androgen-independent therapy-resistant prostate tumors, unlike most Androgen Receptor-binding anti-Androgenic drugs currently on the market, which are only intended for Androgen-dependent tumors. The Company’s co-leading candidate, CPC-200, is a molecularly-targeted oxidase enzyme inhibitor drug that irreversibly binds to and inactivates the oxidase enzyme-producing hydrogen peroxide in the cell cytoplasm, and is intended for the treatment of high-risk, solid, recurring cancer patients. This earlier-stage biotechnology is establishing global collaborations to further its research. |
|
| Products / Services |
CPC-100 is an antioxidant, anti-inflammatory and anti-androgenic oxidative stress inhibitor drug. It is used to treat patients receiving follow-up treatment for primary prostate cancer that are returning to the clinic with rising Prostate Specific Antigen (PSA) levels without evidence of tumor metastasis in bone or soft tissue.
|
|
| Technology / Differentiation |
| There is an existing billion-dollar-plus market in drugs for prostate cancer patient populations with mid-stage prostate tumors. If clinical trials are successful, CPC-100 drug sales would strongly compete in this market. CPC-100 acts on multiple targets and benefits both androgen-dependent and androgen-independent prostate cancer. Competitive drugs lack therapeutic effect in androgen-independent prostate cancer. |
|
| Market / Customers |
Prostate cancer is the most commonly diagnosed cancer in men; in the U.S., over 234,000 cases were diagnosed in 2006. It is also the leading cause of cancer fatality among U.S. men, directly causing over 27,000 deaths each year. Currently, there is no effective therapy for advanced prostate cancer.
|
|
| Status |
| Colby plans to file its first investigational New Drug application to FDA and will sponsor a Phase I/IIa clinical trial for its lead drug, CPC-100, for the treatment of men with progressive prostate cancer. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members